

Table 35.1
Comparison of 5-Year Relative Survival^a(Percent) using different Expected Survival Life Tables
By Primary Cancer Site, Race and Sex, 2008-2014

Site	All Races				White				Black			
	Male		Female		Male		Female		Male		Female	
	USLT ^b	SES ^c										
All Sites	66.4	66.4	67.5	67.5	66.6	66.5	68.2	68.1	63.7	63.6	59.1	59.1
Oral Cavity & Pharynx	64.0	64.0	67.0	66.9	65.8	65.8	67.6	67.5	46.0	46.0	52.9	53.0
Lip	87.6	88.2	89.7	89.3	87.4	88.0	89.9	89.5	66.8	66.8	67.3	67.3
Tongue	66.2	66.1	64.8	64.8	68.1	68.0	66.1	66.0	42.9	42.9	43.7	43.7
Salivary gland	64.1	64.0	82.3	82.1	61.9	61.8	81.0	80.8	70.5	70.5	81.8	81.8
Floor of mouth	51.8	51.9	55.2	55.2	53.0	53.0	57.4	57.3	43.4	43.4	31.3	31.4
Gum & other oral cavity	55.1	55.2	64.4	64.3	55.2	55.2	63.6	63.5	49.5	49.5	62.4	62.5
Nasopharynx	59.4	59.4	66.8	66.8	57.1	57.1	62.0	61.9	57.4	57.4	55.0	55.1
Tonsil	74.6	74.5	70.8	70.9	76.0	75.9	73.2	73.3	57.2	57.2	48.3	48.3
Oropharynx	47.1	47.1	40.7	40.8	51.0	51.0	42.3	42.4	26.9	27.0	29.0	29.2
Hypopharynx	32.9	32.9	32.5	32.5	36.1	36.0	34.9	35.0	18.2	18.2	16.8	16.8
Other oral cavity & pharynx	47.5	47.7	35.4	35.5	51.4	51.6	39.4	39.6	29.0	29.1	16.5	16.5
Digestive System	41.2	41.2	46.4	46.3	41.6	41.6	47.0	46.8	35.8	35.8	43.3	43.3
Esophagus	18.9	18.9	20.1	20.0	19.9	19.9	20.3	20.3	11.4	11.4	16.1	16.2
Stomach	28.4	28.4	35.3	35.1	27.1	27.0	34.5	34.2	26.4	26.4	37.1	37.0
Small intestine	66.8	66.8	68.5	68.4	67.2	67.2	70.0	69.9	64.1	64.0	63.7	63.8
Colon & Rectum	64.1	64.1	65.1	64.9	64.7	64.7	65.6	65.4	55.8	55.7	59.8	59.8
Colon	63.5	63.6	63.7	63.6	64.4	64.4	64.7	64.5	55.2	55.0	56.9	56.9
Rectum	65.2	65.2	68.7	68.6	65.3	65.3	67.9	67.8	57.3	57.3	68.7	68.7
Anus, anal canal & anorectum	61.0	60.8	71.5	71.4	62.7	62.5	72.7	72.6	52.8	52.9	63.4	63.4
Liver & intrahepatic	17.5	17.5	18.4	18.4	17.0	16.9	17.5	17.5	13.3	13.3	16.2	16.2
bile duct												
Gallbladder	18.4	18.4	18.2	18.1	17.8	17.7	18.4	18.3	15.2	15.3	16.9	17.0
Other biliary	18.9	18.8	16.1	16.1	19.6	19.5	15.3	15.3	11.0	11.0	16.0	16.0
Pancreas	8.8	8.8	8.3	8.3	8.8	8.7	8.1	8.0	7.6	7.6	9.5	9.5
Retroperitoneum	53.0	52.9	55.5	55.4	52.8	52.6	54.5	54.4	59.2	58.9	52.9	52.9
Peritoneum, omentum &	38.4	38.2	31.5	31.5	37.1	36.9	31.1	31.0	34.1	33.8	26.5	26.5
mesentery												
Other digestive system	7.1	7.1	10.2	10.2	7.1	7.0	10.7	10.6	6.0	6.0	6.4	6.4

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015.

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.

Table 35.1
Comparison of 5-Year Relative Survival^a(Percent) using different Expected Survival Life Tables
By Primary Cancer Site, Race and Sex, 2008-2014

Site	All Races				White				Black			
	Male		Female		Male		Female		Male		Female	
	USLT ^b	SES ^c										
Respiratory System	20.1	20.2	23.2	23.3	20.4	20.4	23.3	23.3	17.7	17.7	21.3	21.3
Nose, nasal cavity & middle ear	59.1	59.2	56.7	56.6	62.1	62.2	57.5	57.4	44.0	44.1	56.6	56.6
Larynx	61.3	61.4	58.3	58.4	62.6	62.7	59.5	59.6	52.5	52.5	49.8	50.0
Lung & bronchus	15.4	15.5	21.9	22.0	15.6	15.7	22.0	22.0	13.2	13.2	19.8	19.8
Pleura	24.6	24.7	28.4	28.3	24.9	25.0	14.1	14.1	—	—	58.5	58.6
Trachea & other respiratory organs	53.6	53.6	52.2	52.2	53.7	53.7	53.0	53.0	46.6	46.8	42.7	42.8
Bones & joints	65.1	65.1	69.3	69.2	64.8	64.8	69.5	69.4	66.0	66.0	64.2	64.2
Soft tissue (including heart)	63.8	63.8	65.4	65.3	64.4	64.3	66.2	66.1	59.7	59.7	59.8	59.8
Skin (excl. basal & squamous)	89.3	89.3	93.8	93.6	88.5	88.5	93.3	93.2	77.2	77.2	84.6	84.6
Melanoma of the skin	89.9	89.9	94.3	94.2	89.2	89.2	93.9	93.8	57.3	57.1	71.0	71.0
Other non-epithelial skin	82.6	82.5	87.0	86.7	80.2	80.1	84.5	84.1	90.5	90.6	95.4	95.4
Breast	83.2	83.0	89.8	89.7	85.2	84.9	90.8	90.6	70.8	70.9	81.1	81.2
Breast (in situ)	—	—	69.4	69.3	—	—	70.8	70.7	—	—	55.6	55.7
Female Genital System	—	—	66.3	66.2	—	—	67.9	67.7	—	—	55.5	55.5
Cervix uteri	—	—	81.2	81.1	—	—	83.5	83.4	—	—	61.5	61.6
Corpus uteri	—	—	82.6	82.5	—	—	84.7	84.6	—	—	63.9	64.0
Uterus, NOS	—	—	29.7	29.6	—	—	32.7	32.5	—	—	20.6	20.6
Ovary	—	—	47.4	47.4	—	—	47.4	47.4	—	—	38.5	38.5
Vagina	—	—	47.0	47.0	—	—	47.2	47.2	—	—	44.9	45.0
Vulva	—	—	71.1	71.0	—	—	70.5	70.4	—	—	71.9	71.8
Other female genital system	—	—	53.6	53.6	—	—	52.4	52.4	—	—	56.2	56.2
Male Genital System	98.0	97.9	—	—	98.1	98.0	—	—	96.0	95.9	—	—
Prostate	98.3	98.2	—	—	98.4	98.3	—	—	96.2	96.1	—	—
Testis	95.4	95.3	—	—	95.5	95.4	—	—	91.6	91.8	—	—
Penis	67.2	67.2	—	—	67.1	67.0	—	—	58.7	58.4	—	—
Other male genital system	85.0	84.9	—	—	86.5	86.2	—	—	63.6	63.4	—	—
Urinary System	75.8	75.9	73.9	73.8	76.1	76.1	74.5	74.4	71.3	71.1	68.5	68.6
Urinary bladder	78.0	78.1	73.1	72.9	78.3	78.3	74.3	74.1	67.5	67.1	55.1	55.0
Kidney & renal pelvis	73.7	73.7	75.8	75.8	73.7	73.6	75.8	75.8	74.2	74.2	76.1	76.3
Ureter	48.1	48.3	45.6	45.4	48.7	48.8	47.6	47.4	28.2	28.1	33.4	33.4
Other urinary system	54.0	54.2	37.9	37.7	53.3	53.5	40.2	39.9	44.8	44.8	17.9	18.0

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015.

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.

Table 35.1
Comparison of 5-Year Relative Survival^a(Percent) using different Expected Survival Life Tables
By Primary Cancer Site, Race and Sex, 2008-2014

Site	All Races				White				Black			
	Male		Female		Male		Female		Male		Female	
	USLT ^b	SES ^c										
Eye & Orbit	82.3	82.4	83.5	83.6	81.3	81.4	82.7	82.8	86.4	86.3	93.2	93.2
Brain & Nervous System	32.0	32.0	34.8	34.7	30.8	30.7	33.7	33.6	38.1	38.1	40.9	40.9
Brain	29.4	29.4	31.1	31.1	28.3	28.2	30.0	30.0	34.9	35.0	36.6	36.6
Cranial nerves & other nervous system	75.7	75.6	82.1	82.0	76.4	76.3	83.7	83.6	74.1	74.2	75.7	75.7
Endocrine System	92.2	92.1	97.8	97.7	92.8	92.7	98.1	98.0	85.5	85.5	95.8	96.0
Thyroid	95.7	95.6	98.9	98.8	96.0	95.8	99.0	99.0	92.9	92.9	97.7	97.7
Other endocrine & thymus	64.6	64.5	64.5	64.4	64.0	63.9	63.3	63.1	63.0	63.1	67.1	67.1
Lymphoma	72.1	72.0	75.4	75.3	72.4	72.3	75.6	75.5	66.7	66.7	73.1	73.2
Hodgkin lymphoma	85.8	85.7	87.8	87.7	86.3	86.2	87.8	87.7	80.3	80.4	87.8	87.8
Non-Hodgkin lymphoma	69.9	69.9	73.4	73.3	70.3	70.2	73.8	73.6	63.4	63.3	69.6	69.6
Myeloma	50.7	50.6	50.9	50.9	50.2	50.1	49.9	49.8	51.5	51.3	52.8	52.8
Leukemia	62.5	62.5	60.1	60.0	62.7	62.7	60.7	60.6	57.0	56.9	53.7	53.6
Lymphocytic	80.3	80.3	78.9	78.8	80.4	80.4	79.3	79.3	72.3	72.1	67.5	67.4
Acute lymphocytic	67.8	67.8	68.6	68.5	67.6	67.5	69.1	69.1	66.0	66.0	60.2	60.2
Chronic lymphocytic	84.4	84.4	83.9	83.8	84.4	84.4	83.9	83.9	74.6	74.3	71.5	71.2
Other lymphocytic	85.2	85.0	70.2	70.2	85.9	85.7	71.6	71.6	71.0	70.7	49.3	49.2
Myeloid & Monocytic	40.2	40.1	40.8	40.7	39.1	39.1	39.9	39.9	42.7	42.7	44.7	44.8
Acute myeloid	26.4	26.3	28.6	28.6	25.9	25.9	28.0	28.0	26.5	26.5	30.9	30.9
Chronic myeloid	66.4	66.4	69.3	69.3	65.4	65.4	68.0	68.0	67.8	67.8	72.2	72.3
Acute monocytic	21.3	21.3	25.4	25.4	21.7	21.7	26.4	26.4	21.1	21.1	28.4	28.4
Other myeloid & monocytic	36.8	36.7	31.3	31.5	32.6	32.6	31.0	31.2	49.1	48.8	28.1	28.2
Other leukemia	33.2	33.2	34.5	34.5	32.3	32.3	35.2	35.1	36.5	36.4	33.3	33.3
Other acute leukemia	23.5	23.5	23.4	23.4	23.9	23.8	22.9	22.8	18.1	18.0	27.0	27.1
Aleukemic, subleukemic & NOS	40.6	40.6	42.1	42.1	39.2	39.2	44.3	44.2	45.1	45.0	35.1	35.1
Miscellaneous	21.6	21.6	14.8	14.8	22.9	22.9	14.8	14.8	12.5	12.5	14.1	14.1
Kaposi Sarcoma	74.2	73.9	74.9	73.5	76.7	76.3	82.7	81.7	65.4	65.4	33.8	33.8
Mesothelioma	7.0	7.0	16.6	16.6	7.0	7.0	15.9	15.9	7.0	7.0	25.8	25.8
Ill-defined & unspecified	100.0	100.0	100.0	100.0	100.0	99.9	100.0	100.0	78.3	78.3	100.0	100.0

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015.

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.